The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.

INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.

The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.

But the former is paying a fraction of what Merck shelled out for raludotatug.

Casdatifan might have found its sweet spot, as part of a Cabometyx combo.

Ibtrozi breezes through FDA review and gives Nuvation its first approval.